# Maximizing Outcomes in Treating Acute Migraine

> **NCT03896009** · PHASE3 · COMPLETED · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 1594 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** AXS-07 (MoSEIC meloxicam and rizatriptan)
- **DRUG:** Meloxicam
- **DRUG:** Rizatriptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03896009
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-04
- **Primary completion:** 2019-12-10
- **Final completion:** 2019-12-10
- **Target enrollment:** 1594 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896009, "Maximizing Outcomes in Treating Acute Migraine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03896009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*